Sigilon Therapeutics, Inc.

Vertex remains bullish on prospects for developing curative, endogenous insulin-sparing cell therapies for type 1 diabetes, despite disappointing results unveiled on 28 March that led the Boston-based

Confidence in a potential curative treatment for Type 1 diabetes is growing after Vertex showed three people given its cell therapy, VX-880, lived without insulin injections for a year. New data fro

The road to starting up and funding a new biopharmaceutical venture is paved with plenty of speedbumps, but certain big pharma companies and investors have made efforts to smooth the path for start-up

Growth in pharma’s pipeline picked up again last year but oncology’s contribution to the whole slackened as companies appeared to spread their R&D bets more broadly. So suggest the latest data from Ci